GKSL Acquires 51% Stake in UAE's Blue Tree Clinics for ₹19.84 Crore; Appoints New Director
Gujarat Kidney And Super Speciality Limited will acquire a 51% stake in UAE-based Blue Tree Clinics LLC for ₹19.84 crore. The acquisition is expected to be completed within 50 days. The company also appointed Mr. (Dr) Paresh Dhoti as an Additional Non-Executive Independent Director.
The acquisition of a majority stake in an international entity represents a significant strategic expansion for the company, potentially impacting future revenue and market presence.
The company is expanding its business through a strategic acquisition and appointing a new director, indicating growth and positive development.
Gujarat Kidney And Super Speciality Limited (GKSL) announced a significant strategic move following its Board Meeting on July 9, 2026. The company will acquire a 51% majority stake in Blue Tree Clinics LLC, a polyclinic based in Dubai, UAE, through a Share Purchase Agreement. This acquisition is valued at ₹19.84 crore, payable in two tranches, and is expected to be completed within 50 days. Blue Tree Clinics, established in 2012, offers services including Plastic Surgery, Laser Cosmetic, General Dental, and Chiropractic care. In FY2025, the UAE entity reported a gross revenue of AED 10,538,978 (approximately ₹24.50 crore) and a net profit of AED 31,38,809 (approximately ₹7.25 crore). This expansion into a new geography and service set aims to broaden GKSL's existing business.
In addition to the acquisition, the Board of Directors has appointed Mr. (Dr) Paresh Dhoti as an Additional Non-Executive Independent Director, effective from July 9, 2026, for a term of five years, subject to shareholder approval. Dr. Dhoti, with 18 years of independent practice as a Dentist in Vadodara, is not related to any existing directors of GKSL.
The company also informed that it will conduct a postal ballot to seek shareholder approval for a variation in the objects of its Initial Public Offering (IPO). Further details regarding this will be filed separately.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.